MetaCap

Solid Biosciences Inc. (SLDB)

NASDAQ: SLDBHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

6.25-0.19 (-2.95%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SLDB stock chart

Technical analysis

Key statistics

All statistics
Market cap
$697.57M
EPS (TTM)
-$1.76
52-week range
4.65 – 11.45
Day range
6.20 – 6.53
Volume / Avg
1.56M / 1.30M
Beta
—

52-week range

$4.65$11.45

SLDB stock today

Solid Biosciences (SLDB) closed at $6.25 on Nov 20, down 2.95% (-$0.19), versus the S&P 500's 3.70% decline. Shares are 45.4% below their 52-week high of $11.45, set on Jul 6, 2026 and 34.4% above the 52-week low of $4.65, in the middle of the past year's range. SLDB is up 10.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 33.0%.

Solid Biosciences has posted a net loss over the last twelve months (EPS of -$1.76), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Solid Biosciences

Company profile

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Alexander G. Cumbo
Headquarters
Charlestown, MA
Employees
121
IPO year
2018

Financial highlights

Full financials

Solid Biosciences reported a net loss of $174.3 million, compared with a loss of $124.7 million a year earlier. Diluted earnings per share came in at -$1.99.

Solid Biosciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue———$8.09M$13.62M
Growth———-40.57%—
Net income$-174.32M$-124.70M$-96.02M$-85.98M$-72.19M
EPS (diluted)$-1.99$-3.06$-4.83$-10.10$-10.14

Analyst forecast

Forecast

Consensus (15 analysts)

strong_buy

Avg. price target

$18.71+199.36%

  • Strong buy 5
  • Buy 10
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $11.00High $26.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-0.36 vs $-0.37
Surprise
+2.70%

SLDB news

All SLDB news

Solid Biosciences peers

Health Care sector
SLDB peer companies
CompanyPrice% ChgMarket capCompare
ATTOAttovia Therapeutics Inc.15.10-3.08%$690.26Mvs SLDB
AURAAura Biosciences Inc.6.87-1.58%$714.99Mvs SLDB
GLUEMonte Rosa Therapeutics Inc.8.64-3.03%$738.29Mvs SLDB
IAMIambic Therapeutics Inc.13.11-8.06%$621.42Mvs SLDB
MGTXMeiraGTx Holdings plc7.98-1.97%$779.89Mvs SLDB
PRMEPrime Medicine Inc.3.55-7.55%$791.62Mvs SLDB
SRZNSurrozen Inc.28.46-7.21%$596.40Mvs SLDB
BBTXBambusa Therapeutics Inc.16.00+2.89%$815.08Mvs SLDB

Indexes, lists and sector

Solid Biosciences stock FAQ

What is Solid Biosciences's stock price today?

SLDB last traded at $6.25 as of Nov 20, 4:00 PM EST, down 2.95% on the day. Prices are delayed at least 15 minutes.

Does Solid Biosciences pay a dividend?

No. Solid Biosciences does not currently pay a regular cash dividend.

Who is Solid Biosciences's CEO?

Mr. Alexander G. Cumbo is the chief executive officer of Solid Biosciences Inc., which has about 121 employees.

Has SLDB ever split its stock?

Yes. The most recent SLDB stock split was a 1-for-15 split on Oct 28, 2022.

What is the SLDB 52-week high?

The 52-week high for SLDB is $11.45 and the 52-week low is $4.65. The stock is currently 45.4% below its high.

Compare SLDB